The short version of DAC fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-05-02. Anything still debated is marked as such rather than presented as settled.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
It is possible to distinguish these sources by analyzing this oil by high-temperature gas chromatography–mass spectrometry. The oil and plasticizer must be separated from the C-4 sample, typically by using a non-polar organic solvent such as pentane followed by solid phase extraction of the plasticizer on silica. This method of analysis is limited by manufacturing variation and methods of distribution.
Levobunolol (trade names AKBeta, Betagan, Vistagan, among others) is a non-selective beta blocker. It is used topically in the form of eye drops to manage ocular hypertension (high pressure in the eye) and open-angle glaucoma.
== Life and education == Masur was born in The Bronx, New York City. Her parents were Polish Jewish immigrants who pushed Masur's academic ambitions. She majored in art at the High School of Music and Art in NYC, and chose a career in science after majoring in Biology and Aesthetics at City College of New York (CCNY), where she earned a Bachelor of Arts in 1960. To this day, Masur feels that for her, "art and science have always been intertwined" and that her artistic background influences her scientific acumen. Masur established the first electron microscopy facility at CCNY when she returned as an Assistant Professor after earning a Masters in Zoology in 1963, followed by a PhD in Cell Biology in 1967 both from Columbia University. She began her research as an undergrad in the laboratory of William Etkin and was mentored at Columbia by Lee Peachy in electron microscopy which she combined with cellular endocrinology to demonstrate hypothalamic inhibition of prolactin secretion. She studied cytochemistry as a postdoctoral fellow in the laboratory of Eric Holtzman at Columbia University. Masur has two sons and two step-daughters.
Ultimately, the potential for different methods of droplet creation and analysis in directed evolution droplet-based microfluidic devices allows for a variability that facilitates a large population of potential candidates for directed evolution. As a method for protein engineering, directed evolution has many applications in fields from development of drugs and vaccines to the synthesis of food and chemicals. A microfluidic device was developed to identify improved enzyme production hosts (i.e., cell factories) that can be employed industrially in various fields. An artificial aldolase was further enhanced by 30-fold using droplet-based microfluidics so that its activity resembled that of naturally occurring proteins. More recently, the creation of functional oxidases has been enabled by a novel microfluidic device created by Debon et al. The droplet-based microfluidic approach to the directed evolution has a great potential for the development of a myriad of novel proteins.
Sources: en.wikipedia.org
They also stated that on May 26, they had gone to the Ministry of Justice to file an official complaint against Filema Duarte, but the Ministry of Justice had rejected any claim that Filema Duarte was not the duly elected Grand Master of Cuba. They stated that a Ministry of Justice official named Miriam García, Director of the Office of Associations, had been interceding directly on behalf of Filema Duarte. On June 21, 2025, Kessel Linares was summoned to appear at the Infanta y Manglar Police Station, where he was interrogated and threatened with charges of disturbing the peace by a State Security officer with a violent reputation of the mistreatment of anti-government dissidents, Lieutenant Colonel Kenia María Morales Larrea.
In recruitment for residency positions less emphasis is often placed on the number of months a candidate has worked after finishing their internship, but it is common for physicians to work for some time in between internship and residency, much in the same way as between medical school and internship.
== History == Desmethylprodine was first synthesized in 1947 at Hoffman-LaRoche Laboratories by Albert Ziering and John Lee. They found that it produced effects similar to morphine when administered to rats. Ziering had been searching for synthetic painkillers that were less addictive than morphine. The new drug was a slight variant of pethidine. It was found to be no more effective than pethidine and was never marketed. This research produced the analgesic alphaprodine (Nisentil, Prisilidine), a very closely related compound. In the United States, MPPP is now in Schedule I of the Controlled Substances Act with a zero aggregate manufacturing quota as of 2014. The free base conversion ratio for salts includes 0.87 for the hydrochloride. It is listed under the Single Convention on Narcotic Drugs and is controlled in most countries in the same fashion as is morphine.
Sources: en.wikipedia.org
=== Basal chordates === Published information on Pikaia gracilens (a well-known Cambrian fossil) explains evolution of swimming ability in chordates related to myomere shape and function. Specifically, myomeres in this species possessed minimal overlap between successive ones and myosepta dividing them were gently curved. In a biomechanical evaluation, it is presumed that Pikaia were not capable of rapid swimming like in living chordates. Several theories for this idea include lacking fast-twitch muscle fibers, ancestral muscle fiber types more like modern slow-twitch fibers, and less tension on myosepta due to less overlap between successive myomeres. In amphioxus, myomeres run longitudinally along the length of the body in a "V"-shape. As sequential contraction for swimming occurs, force from the myomeres is transmitted via connective tissues to the notochord.
If this is the case, such a duplication must have happened early in animal evolution (more than 700 million years ago), as genes that encode for all three subunits of troponin have been found in every invertebrate phyla except the Cnidaria (or equivalently, all Bilaterian phyla). The ancestral gene pair most closely resembled TNNI2-TNNT3.
With the all out anti-dissidence campaigns against the Huks, they numbered less than 2,000 by 1954 and without the protection and support of local supporters, active Huk resistance no longer presented a serious threat to Philippine security. From February to mid-September 1954, the largest anti-Huk operation, "Operation Thunder-Lightning" was conducted and resulted in the surrender of Luis Taruc on May 17. Further cleanup operations of guerrillas remaining lasted throughout 1955, diminishing its number to less than 1,000 by year's end.
It has been suggested that snakes evolved the mechanisms necessary for venom formation and delivery sometime during the Miocene epoch. During the mid-Tertiary, most snakes were large ambush predators belonging to the superfamily Henophidia, which use constriction to kill their prey. As open grasslands replaced forested areas in parts of the world, some snake families evolved to become smaller and thus more agile. However, subduing and killing prey became more difficult for the smaller snakes, leading to the evolution of snake venom. The most likely hypothesis holds that venom glands evolved from specialized salivary glands. The venom itself evolved through the process of natural selection; it retained and emphasized the qualities that made it useful in killing or subduing prey. Today we can find various snake species in stages of this hypothesized development. There are the highly efficient envenoming machines - like the rattlesnakes - with large capacity venom storage, hollow fangs that swing into position immediately before the snake bites, and spare fangs ready to replace those damaged or lost. Other research on Toxicofera, a hypothetical clade thought to be ancestral to most living reptiles, suggests an earlier time frame for the evolution of snake venom, possibly to the order of tens of millions of years, during the Late Cretaceous. Snake venom is produced in modified parotid glands normally responsible for secreting saliva. It is stored in structures called alveoli behind the animal's eyes and ejected voluntarily through its hollow tubular fangs.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.